BioCentury
ARTICLE | Company News

Alkermes in pay-for-performance deal

August 31, 2018 3:12 PM UTC

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence.

Alkermes spokesperson Matthew Henson did not disclose the specific outcome measures attached to reimbursement, but said the intention of the contract is "to encourage patients to stay in treatment longer and meet treatment goals established by patients and their physicians."...

BCIQ Company Profiles

Alkermes plc